A Phase 1, First-in-Human, Open-label, Multicenter Study of JZP898 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors

Sponsor:

Jazz Pharmaceuticals

Sponsor Study ID:

JZP898-101

CTO #:

104233

NCT Number:

NCT06108050

Phase:

Early Phase I

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Bladder; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Lung; Melanoma, Skin

Study Objectives:

To determine the MonoRD and/or MTD (or highest cleared DL) of JZP898 as well as the CombiRD of JZP898 in combination with pembrolizumab. To characterize the safety and tolerability profile of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)